High serum levels of vascular endothelial growth Factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy

Annals of Surgical Oncology

Volumn 21, Issue 7, 2014, Pages 2361-2368

  Cheng, Jason Chia Hsien ^a,b,c   Graber, Madeline S ^a   Hsu, Feng Ming ^b   Tsai, Chiao Ling ^b   Castaneda, Leon ^a   Lee, Jang Ming ^b   Chang, Daniel T ^a   Koong, Albert C ^a  

^a STANFORD UNIVERSITY   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASSAY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PROXIMITY LIGATION ASSAY; TREATMENT OUTCOME; BLOOD; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902214358     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3611-z     Document Type: Article

References (21)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Ko CY, Bentrem DJ. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Ann Surg Oncol. 2012;19:357-64.
3. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.
4. Hsu FM, Lee JM, Huang PM, et al. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:e593-9.
5. Jayachandran P, Pai RK, Quon A, et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:471-7.
6. Owaki T, Matsumoto M, Okumura H, et al. Endoscopic ultrasonography is useful for monitoring the tumor response of neoadjuvant chemoradiation therapy in esophageal squamous cell carcinoma. Am J Surg. 2012;203:191-7.
7. Luthra R, Luthra MG, Izzo J, et al. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol. 2006;33:S2-5.
8. Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 2009;250:729-37.
9. Fredriksson S, Dixon W, Ji H, Koong AC, Mindrinos M, Davis RW. Multiplexed protein detection by proximity ligation for cancer biomarker validation. Nat Methods. 2007;4:327-9.
10. Fredriksson S, Horecka J, Brustugun OT, et al. Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem. 2008;54:582-9.
11. Chang ST, Zahn JM, Horecka J, et al. Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med. 2009;7:105.
12. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721-4.
13. Hsu FM, Lee YC, Lee JM, et al. Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy. Ann Surg Oncol. 2009;16:1669-77.
14. Gannett DE, Wolf RF, Takahashi GW, et al. Neoadjuvant chemoradiotherapy for esophageal cancer using weekly paclitaxel and carboplatin plus infusional 5-fluorouracil. Gastrointest Cancer Res. 2007;1:132-8.
15. Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer. 2001;92:663-9.
16. Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 2004;87:95-104.
17. Sun SP, Jin YN, Yang HP, Wei Y, Dong Z. Serum transforming growth factor-beta1 level reflects disease status in patients with esophageal carcinoma after radiotherapy. World J Gastroenterol. 2007;13:5267-72.
18. McDonnell CO, Harmey JH, Bouchier-Hayes DJ, Walsh TN. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. Br J Surg. 2001;88:1105-9.
19. Kashyap MK, Harsha HC, Renuse S, et al. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther. 2010;10:796-810.
20. Noma K, Smalley KS, Lioni M, et al. The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology. 2008;134:1981-93.
21. Gholamin M, Moaven O, Memar B, et al. Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg. 2009;33:1439-45.